Fig. 10: Detection of CX-5461-sensitivity gene expression signature in primary and relapsed HGSOC samples. | Nature Communications

Fig. 10: Detection of CX-5461-sensitivity gene expression signature in primary and relapsed HGSOC samples.

From: CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer

Fig. 10

a Clinical and RNA-seq gene expression data from 81 primary ovarian tumour samples from the Australian cohort of ovarian cancer patients from the International Cancer Genome Consortium (ICGC) [https://dcc.icgc.org/] (release 27). The level of expression of the CX-5461 sensitivity signatures were calculated using ssGSEA in individual samples. ssGSEA scores were normalized by linear transformation to the 0–1 range for comparison. b ssGSEA scores were calculated as in (a) in 25 ascites samples from relapse patients from the ICGC. c Clustering of ascites samples from relapse patients with cell lines was based on the MYC_UP-sig and BRCAm-sig signatures using k-means with a k = 4. d Analysis of the MYC_UP-sig and BRCAm-sig in three matching primary tumour samples of three relapsed samples in (c) enriched with CX-5461-sensitivity signature. e Clustering of samples in E with cell lines samples based on the MYC_UP-sig and BRCAm-sig signatures using k-means with a k = 4.

Back to article page